Abiomed, Inc. and Subsidiaries Consolidated Statements of Operations (Unaudited) (in thousands, except per share data)

| | | Three Months Ended March 31, | | | Fiscal Years Ended March 31, | | | |
|---|----|------------------------------------|----|--------|---------------------------------|---------|----|---------|
| | | 2017 | | 2016 | | 2017 | | 2016 |
| Revenue: | | | | | | | | |
| Product revenue | \$ | 124,654 | \$ | 93,951 | \$ | 445,195 | \$ | 329,520 |
| Funded research and development | | 26 | | 6 | | 109 | | 23 |
| | | 124,680 | | 93,957 | | 445,304 | : | 329,543 |
| Costs and expenses: | | | | | | | | |
| Cost of product revenue | | 19,261 | | 14,663 | | 70,627 | | 50,419 |
| Research and development | | 16,325 | | 14,225 | | 66,386 | | 49,759 |
| Selling, general and administrative | | 60,100 | | 45,256 | | 218,153 | | 164,261 |
| | | 95,686 | | 74,144 | | 355,166 | | 264,439 |
| Income from operations | | 28,994 | | 19,813 | | 90,138 | | 65,104 |
| Other income: | | | | | | | | |
| Investment income, net | | 486 | | 186 | | 1,554 | | 395 |
| Other (expense) income, net | | (124) | | 228 | | (349) | | 339 |
| | | 362 | | 414 | | 1,205 | | 734 |
| Income before income taxes | | 29,356 | | 20,227 | | 91,343 | | 65,838 |
| Income tax provision | | 14,457 | | 9,229 | | 39,227 | | 27,691 |
| Net income | \$ | 14,899 | \$ | 10,998 | \$ | 52,116 | \$ | 38,147 |
| Basic net income per share | \$ | 0.34 | \$ | 0.26 | ¢ | 1.21 | \$ | 0.90 |
| Basic weighted average shares | Ψ | 0.54 | Ψ | 0.20 | Ψ | 1.21 | Ψ | 0.30 |
| outstanding | | 43,579 | | 42,463 | | 43,238 | | 42,204 |
| Diluted net income per share | \$ | 0.33 | \$ | 0.24 | \$ | 1.17 | \$ | 0.85 |
| Diluted weighted average shares outstanding | | 44,924 | | 45,112 | | 44,658 | | 44,895 |